Acute Leukemia News

• A Guide to the New Agents Reshaping Ovarian Cancer Treatment Dr Rebecca Stone on the 'exciting, diversified landscape' of recent and emerging treatments for ovarian cancer.
  Medscape Medical News, October 30, 2020
• 'Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL Chemo-free targeted therapy yielded high rates of molecular response, "impressive" survival at 18 months with few toxic effects in a phase 2 trial of adults with Ph+ acute lymphoblastic leukemia (ALL).
  Medscape Medical News, October 21, 2020
• Non-Whites Sorely Underrepresented in Phase 3 Psoriasis Trials Participation by non-White patients in phase 3 therapeutic trials for plaque psoriasis is less than 15%.
  Medscape Medical News, October 21, 2020
• First-in-Class Oral EZH2 Inhibitor Effective in Two Cancers Phase 2 results hint at the power of epigenetic targets.
  Medscape Medical News, October 19, 2020
• New Guideline Helps Patients and Parents Navigate Pediatric ALL A new guideline from the National Comprehensive Cancer Network (NCCN) provides information about pediatric ALL to patients and their families in an easy-to-learn format.
  Reuters Health Information, October 07, 2020
• A Uniquely Patient-Focused Take on Treating AML in Older Adults Dr Mikkael Sekeres discusses how the recent ASH guidelines, on which he is a coauthor, are meant to guide the difficult decisions that follow a new diagnosis of AML in older patients.
  Medscape Medical News, October 05, 2020
• Orthopedic Problems in Children Can Be the First Sign of ALL The diagnosis of acute lymphoblastic leukemia (ALL) can be delayed because of vague presentation and normal hematological results.
  Medscape Medical News, October 02, 2020
• Alert FDA Approves First Maintenance Therapy for AML The FDA has approved an oral formulation of azacitidine for the continued treatment of adults with acute myeloid leukemia (AML) who have achieved initial complete remission.
  FDA Approvals, September 02, 2020
• Azacitidine + Venetoclax Combo Benefits Older Patients With AML The treatment regimen improved overall survival and remission rates with rapid responses in the tough-to-treat population of older patients with acute myeloid leukemia (AML).
  Medscape Medical News, August 12, 2020
• In Remission for 10 Years: Long-term Toxicity Data on CAR T Cells After wrestling with early toxicity, one of the first patients to receive CAR T-cell therapy is still in remission after 10 years. Longer-term data are accumulating for these therapies, dubbed 'living drugs.'
  Medscape Medical News, July 21, 2020
• 'Fingerstick' Assay Identifies Exposure to Toxic Radiation Levels Although still experimental, a novel test could rapidly identify exposure levels of radiation in patients with cancer, as well as others who may have acute radiation sickness.
  Medscape Medical News, July 20, 2020
• Don't Overlook Treating Older Patients With APL, Expert Says A conversation with Dr Heidi Klepin on why this subtype of acute myeloid leukemia is surprisingly treatable in older patients, if quickly identified.
  Medscape Medical News, July 17, 2020
• Alert FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML).
  FDA Approvals, July 08, 2020
• EHA 2020 Venetoclax Plus LDAC Tops LDAC Alone in AML Cytarabine plus venetoclax showed benefit in overall survival for treatment naive AML patients.
  Medscape Medical News, June 29, 2020
• EHA 2020 Novel Drug Imetelstat Shows Transfusion Independence in MDS The novel telomerase inhibitor allowed patients with lower-risk myelodyplastic syndrome (MDS) who were heavily dependent on transfusions to become transfusion independent for a median of 20 months.
  Medscape Medical News, June 23, 2020
• EHA 2020 Omitting Whole Body Irradiation Before HSCT: Trial Stopped Early A study to evaluate a chemo-conditioning only approach -- without total body irradiation -- before hematopoietic stem cell transplantation was stopped early as outcomes clearly favored irradiation.
  Medscape Medical News, June 15, 2020
• EHA 2020 Three-Drug Combo Promising Against High-Risk CLL The combination of obinutuzumab, ibrutinib, and venetoclax was associated with a high complete response rate in patients with high-risk chronic lymphocytic leukemia, a phase 2 trial finds.
  Medscape Medical News, June 15, 2020
• RUNX1 Transcription Factor Maintains Acute Myeloid Leukemia Stem Cells The RUNX1 transcription factor plays a key role in the maintenance of human acute myeloid leukemia stem cells, researchers report.
  Reuters Health Information, June 08, 2020
• Mixed Outcomes of COVID-19 in Recipients of Bone Marrow Transplants Recipients of bone-marrow transplants who develop COVID-19 can present with mild symptoms but still have high mortality, according to a retrospective study.
  Reuters Health Information, June 05, 2020
• AAN 2020 Nilotinib Is Safe in Moderate and Advanced Parkinson's Disease Although nilotinib is safe and tolerable in patients with moderate or advanced Parkinson's disease, it may not affect the disease's symptoms, according to investigators.
  Medscape Medical News, May 29, 2020